Medtronic has raised its fiscal 2027 revenue-growth forecast and increased the lower end of its adjusted earnings outlook after reporting strong first-quarter demand across its cardiovascular portfolio. The medical technology company said on September 1 that it now expects organic revenue growth of 7.25% to 7.75%, compared with its previous forecast of 6.75% to 7.25%. …
Surrogacy can provide a family-building route when pregnancy is impossible, medically unsafe, or biologically unavailable to an intended parent. It may be considered by people with uterine-factor infertility, some cancer survivors, male same-sex couples, single intended fathers, and others after individualized medical and legal review. Accurate information matters because surrogacy combines assisted reproductive technology, pregnancy …
Zydus Lifesciences’ first-quarter net profit declined 35.9% to ₹9.40 billion, despite strong revenue growth. Revenue from operations increased 22% to ₹80.17 billion, supported by India formulations, international markets and consumer wellness. EBITDA fell 7.6%, while the EBITDA margin narrowed sharply to 24.1% from 31.8% a year earlier. India-based Zydus Lifesciences reported a 35.9% decline in …
The Peptide CDMO Market is gaining strategic importance as pharmaceutical and biotechnology companies increase their investment in peptide-based therapeutics. Rapid growth in GLP-1 medicines, expanding cardiometabolic pipelines and the development of next-generation peptide drugs are creating substantial demand for specialized manufacturing capacity. According to Medi-Tech Insights, the Peptide CDMO Market is projected to grow at …
Germany’s Merck KGaA raised its 2026 profit guidance after second-quarter adjusted earnings exceeded expectations, supported by stronger demand in its Life Science and Electronics businesses and easing currency pressure. The Darmstadt-based science and technology group now expects adjusted earnings before interest, taxes, depreciation and amortisation, or EBITDA, of €5.9 billion to €6.3 billion in 2026. …
The US Food and Drug Administration has approved Moderna’s mFlusiva, making it the first mRNA-based seasonal influenza vaccine cleared for public use. The vaccine is approved for adults aged 50 years and older and is expected to become available in the United States during the 2026–2027 respiratory virus season. The decision represents an important expansion …
Patients with cancer who received glucagon-like peptide-1 receptor agonists were associated with a 34% lower risk of death than nonusers in a large real-world analysis presented at the 2026 American Society of Clinical Oncology Annual Meeting, prompting calls for prospective trials. The analysis examined patients treated in community oncology practices across multiple cancer types. Investigators …
US biotechnology startup Conception has announced that it has generated early-stage human egg cells, known as primary oocytes, from stem cells created from blood samples. The company said the cells remain immature and cannot currently be used for fertilization or pregnancy. The company reported that the achievement involved converting blood cells into induced pluripotent stem …
Prostate cancer remains one of the most commonly diagnosed cancers among men worldwide and continues to be a major healthcare concern in 2026. According to leading cancer research organizations, prostate cancer accounts for a significant percentage of new cancer diagnoses each year, highlighting the ongoing need for more accurate, less invasive diagnostic tools. Recent advancements …
Next-Generation Flexible Robots Are Transforming Minimally Invasive Gastrointestinal Procedures The field of robotic-assisted surgery continues to evolve rapidly in 2026, with flexible robotic endoscopy emerging as one of the most promising innovations in minimally invasive healthcare. Originally pioneered through the MASTER (Master and Slave Transluminal Endoscopic Robot) platform developed by researchers at Nanyang Technological University …